Corcept Therapeutics (CORT) Non Operating Income (2016 - 2026)

Corcept Therapeutics (CORT) has 11 years of Non Operating Income data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 21.22% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (down 19.4% YoY), and the FY2025 full-year result was $21.7 million, down 11.72% from the prior year.
• Non Operating Income slipped to $4.9 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.7 million in Q4 2024 to a low of $80000.0 in Q1 2022.
• A 5-year average of $4.2 million and a median of $5.0 million in 2025 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income sank 70.91% in 2022 and surged 4376.25% in 2023, its largest moves.
• Tracing CORT's Non Operating Income over 5 years: stood at $1.8 million in 2022, then surged by 189.25% to $5.1 million in 2023, then soared by 30.31% to $6.7 million in 2024, then declined by 19.04% to $5.4 million in 2025, then dropped by 9.9% to $4.9 million in 2026.
• Business Quant data shows CORT's Non Operating Income at $4.9 million in Q1 2026, $5.4 million in Q4 2025, and $5.0 million in Q3 2025.